Generic Drug Manufacturer Hikma Providing Credits for 340B Overcharges

Hikma Pharmaceuticals USA, the U.S. division of U.K.-based generic drug manufacturer Hikma Pharmaceuticals plc, is crediting 340B covered entities for overcharges on a long list of NDCs from the fourth quarter of 2017 through the fourth quarter of 2020.

The company announced the credits in a notice posted last week on the U.S. Health Resources and Services Administration website. Apexus, the 340B prime vendor, is working with wholesalers to process the credits on Hikma’s behalf.

Tom Mirga

Website | + posts

• Tom Mirga

  https://340breport.com/author/tom-mirga340breport-com/

  Health Center Challenging 340B Patient Definition Responds to HRSA’s and Drug Companies’ Court Arguments
• Tom Mirga

  https://340breport.com/author/tom-mirga340breport-com/

  Novo Nordisk Providing 340B Refunds on Blockbuster Drug Ozempic
• Tom Mirga

  https://340breport.com/author/tom-mirga340breport-com/

  HRSA Grants 340B Enrollment Flexibility in Georgia Due to Hurricane
• Tom Mirga

  https://340breport.com/author/tom-mirga340breport-com/

  Sanofi Withdraws Some Health Centers’ 340B Pricing at Contract Pharmacies